Navigation Links
Drug Company Halts Late-Stage Trial of Sickle-Cell Disease Drug

Drug manufacturer Icagen announced that it has ended its Phase III clinical trial of its sickle-cell treatment senicapoc, citing lack of effectiveness//, the Raleigh News & Observer reports.

Sickle-cell disease is a genetic blood disorder primarily affecting blacks, but can also be found Hispanics and people from the Middle East, Southeast Asia and the Mediterranean region.

Final testing in the 160-participant senicapoc study began in February 2005, and concerns about the treatment's effectiveness arose in August 2006 after the study's data monitoring committee suggested that senicapoc likely would benefit only a small number of people.

Icagen and Johnson & Johnson -- which paid $15 million to market and help develop the drug -- at that point decided to adjust the number of participants and treatment options being tested in the trial.

Recently, the committee said preliminary trial data show that senicapoc does not prevent chronic pain, one of the disease's most prominent complications. However, the drug consistently has been able to reduce the number of deformed blood cells associated with the disease. That effect "might make the drug suitable to reduce elevated blood pressure in the lungs of some sickle-cell patients and the stroke risk for pediatric sickle-cell patients," according to the News & Observer.

Currently, there is only one other treatment available for the disease. Richard Katz, Icagen's senior vice president of finance and corporate development, said that despite the findings, "it would be premature to say senicapoc is dead." He said the drug's future should be clearer in a few months.

Source-Kaiser Family Foundation/M
'"/>




Page: 1

Related medicine news :

1. Problems Of a Growing Company
2. Teenagers Take More Risk-Taking Behaviors In The Company Of Same Sex Friends
3. Australian Company Gets $10 million For Developing Skin Cancer Gel
4. Elderly People Prefer The Company Of Pet Dogs
5. Ossur Acquires the U.S. Orthopaedics Company
6. Britain Approves Indian Company For Supplying Medicines
7. Drug Company Admits Knowledge Of Side Effects In Monkeys
8. Ranbaxy Expands By Acquiring A Generic Company In Belgium
9. Indian Training Company To Train Children In Dubai, Sharjah
10. GE Healthcare to Acquire Swedish Medical Company
11. Drug Company Seeks Approval for Human Testing of Vaccine against H5N1 Virus
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/5/2016)... Dickson, Tennessee (PRWEB) , ... February 05, 2016 ... ... State Community College President George H. Van Allen have signed a joint enrollment ... semester, provides a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. ...
(Date:2/5/2016)... ... February 05, 2016 , ... In the fourth quarter ... gathered at the La Valencia Hotel in San Diego, California to discuss changes ... the year’s most outstanding franchise, walking away with the coveted David Wright Award ...
(Date:2/5/2016)... ... , ... Boar’s Head Brand®, one of the nation’s leading providers of premium ... the stress out of your party preparation – follow these easy, yet delicious recipes ... the game. , “The key to hosting a successful game-day party is creating a ...
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS is ... to provide the most effective tattoo removal today, Dr. Bentkover is the only doctor ... by Cynosure, the PicoSure has been approved by the Food and Drug Administration (FDA) ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a topic that should ... event they are experiencing an illness. Migraines are a severe form of a headache ... migraines would not wish the pain on their worst enemy, the feeling can last ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... Feb. 5, 2016  Aralez Pharmaceuticals Inc. ("Aralez") today ... Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval ... of Tribute. The combined company will operate under Aralez ... operations in Canada , ... . Under the terms of the Agreement and ...
(Date:2/5/2016)... Feb. 5, 2016  Venice,s newest laser clinic, ... first of its kind in the area and ... advanced laser treatment. The physician-owned and operated laser ... Suncoast by storm with its revitalizing skin care ... multi-wavelength Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
(Date:2/5/2016)... WARSAW, Ind. , Feb. 5, 2016  Zimmer ... the pricing of the previously announced underwritten secondary offering ... of its stockholders, consisting of affiliates of Blackstone and ... public at an initial price of $96.45 per share. ... of the offering.  Neither Zimmer Biomet nor any of ...
Breaking Medicine Technology: